| P50 | author | Torsten Zuberbier | Q124962 |
| | Marcus Maurer | Q50039778 |
| P2860 | cites work | The diagnosis and management of acute and chronic urticaria: 2014 update. | Q38207184 |
| | The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update | Q38208428 |
| | Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria | Q38217720 |
| | Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review | Q38223260 |
| | Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis | Q39220250 |
| | Effect of omalizumab on patients with chronic urticaria | Q39331269 |
| | Quality of life in chronic urticaria: a survey at a public university outpatient clinic, Botucatu (Brazil). | Q42496255 |
| | Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy | Q43013007 |
| | Selected urticaria patients benefit from a referral to tertiary care centres--results of an expert survey | Q43447828 |
| | Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients | Q47257091 |
| | Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice | Q47960148 |
| | Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. | Q51455335 |
| | Effects of omalizumab in a patient with three types of chronic urticaria. | Q52882290 |
| | Real-life experiences with omalizumab for the treatment of chronic urticaria. | Q54327169 |
| | Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria | Q56962717 |
| | Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab | Q56962722 |
| | Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy | Q28264284 |
| | The impact of chronic idiopathic urticaria on quality of life in korean patients | Q33816916 |
| | Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. | Q34035726 |
| | Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report | Q34150295 |
| | A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria | Q34200855 |
| | Experiences with monoclonal antibody therapy for allergic asthma | Q34332936 |
| | Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy | Q34354169 |
| | Treatment of chronic autoimmune urticaria with omalizumab | Q34822193 |
| | Successful treatment of solar urticaria with anti-immunoglobulin E therapy | Q34858119 |
| | Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma | Q35574100 |
| | 10 years experience of the Dermatology Life Quality Index (DLQI). | Q35745472 |
| | Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. | Q36496397 |
| | Allergic diseases and their impact on quality of life | Q36636412 |
| | Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. | Q37061738 |
| | Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma | Q37778201 |
| | Safety of omalizumab in asthma | Q37852717 |
| | Treatment of refractory chronic urticaria: current and future therapeutic options | Q38148494 |
| | Chronic spontaneous urticaria: etiology and pathogenesis | Q38164937 |
| P433 | issue | 2 | |
| P921 | main subject | chronic urticaria | Q3886240 |
| | urticaria | Q187440 |
| P304 | page(s) | 171-180 | |
| P577 | publication date | 2015-01-07 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Omalizumab for the treatment of chronic urticaria | |
| P478 | volume | 11 | |